National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 1) (PB 8 of 2021) (Cth)
PB 8 of 2021
National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 1)
I, Thea Connolly, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following Determination.
Dated 27 January 2021
THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 1).
This instrument may also be cited as PB 8 of 2021
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 February 2021. | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
1 Schedule 1, entry for Ezetimibe and Ezetimibe and rosuvastatin
Omit
| Ezetimibe | Tablet 10 mg | Ezetrol | 30 | 12.71 | 15.50 |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Rosuzet Composite Pack | 1 | 14.27 | 17.06 |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Rosuzet Composite Pack | 1 | 15.02 | 17.81 | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Rosuzet Composite Pack | 1 | 15.96 | 18.75 | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Rosuzet Composite Pack | 1 | 17.35 | 20.14 |
Substitute
| Ezetimibe | Tablet 10 mg | Oral | Ezetrol | 30 | 12.71 | 15.50 |
| Ezetimibe and rosuvastatin | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 14.27 | 17.06 |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 15.02 | 17.81 | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 15.96 | 18.75 | |
| Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Oral | Rosuzet Composite Pack | 1 | 17.35 | 20.14 |
2 Schedule 1, omit entry for entry for Levodopa with carbidopa
3 Schedule 1, after entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg
Insert
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | Sevikar 40/5 | 30 | 8.96 | 11.75 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | Sevikar 40/10 | 30 | 9.60 | 12.39 | |
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 20/5/12.5 | 30 | 6.12 | 8.91 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 | 30 | 10.42 | 13.21 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 11.88 | 14.67 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 11.06 | 13.85 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 | 30 | 12.52 | 15.31 |
4 Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg
omit from the column headed “Claimed Price”: 9.94 substitute: 13.11
5 Schedule 1, entry for Perindopril in the form Tablet containing perindopril arginine 2.5 mg
omit from the column headed “Claimed Price”: 8.24 substitute: 10.51
6 Schedule 1, entry for Perindopril in the form Tablet containing perindopril arginine 5 mg
omit from the column headed “Claimed Price”: 9.18 substitute: 11.45
7 Schedule 1, entry for Perindopril in the form Tablet containing perindopril arginine 10 mg
omit from the column headed “Claimed Price”: 11.03 substitute: 13.30
8 Schedule 1, entry for Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate)
omit from the column headed “Claimed Price”: 10.12 substitute: 11.93
9 Schedule 1, entry Perindopril with amlodipine in the form Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)
omit from the column headed “Claimed Price”: 11.05 substitute: 12.86
10 Schedule 1, entry Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate)
omit from the column headed “Claimed Price”: 11.96 substitute: 13.77
11 Schedule 1, entry Perindopril with amlodipine in the form Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate)
omit from the column headed “Claimed Price”: 12.89 substitute: 14.70
12 Schedule 1, entry for Spironolactone in the form Tablet 25 mg
(a)omit from the column headed “Determined Price”: 4.67 substitute: 3.50
(b)omit from the column headed “Claimed Price”: 11.64 substitute: 8.73
13 Schedule 1, entry for Spironolactone in the form Tablet 100 mg
(c)omit from the column headed “Determined Price”: 18.36 substitute: 13.77
(d)omit from the column headed “Claimed Price”: 25.33 substitute: 19.00
0
0
0